The company reported a net loss of $33.2 million, which is less than the same period last year. During the past year, BioMimetic Therapeutics received FDA clearance on several orthopedic devices and has been working with the regulatory body to obtain approval for its Augment Bone Graft, which was cleared by the Australian Therapeutics Goods Administration during the fourth quarter of last year.
More recently, the company has announced clearance internationally and has made progress on studies for their products.
More Articles on Orthopedic Devices:
17 Spine Devices Receive FDA 510(k) Clearance in February
TranS1 Reports 32% Drop in 4Q Revenue
American Joint Replacement Registry Now Includes 19k Procedures
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
